Page 1
1
SupplementaryAppendix
TableofContents
Inclusioncriteria
Exclusioncriteria
Studydrugadministration
Drugstorageandsupply
Co-primaryendpoints–definitions
Dosefrequencycommittee(DFC)charter
Supplementarytables
TableS1:Doseandfrequencyallocationaccordingtocohort
TableS2:Doseandfrequencyallocationaccordingtopopulation
TableS3:Adverseeventsbyseverityandtypeinthesafetypopulation(N=37)
TableS4:Safetyparameters(safetypopulation)
TableS5:Clinicalfluorescence-activatedcellsorting(FACS)
TableS6:AICforallmodels(analysispopulation)
TableS7:Estimatedtargetdose/frequency
TableS8:Bestestimatedallowabledoes/frequencyaccordingtoMahalanobisdistanceandjointprobability–Lineardose,quadraticfrequency,interaction(analysispopulation)
TableS9:Bestestimatedallowabledose/frequencyaccordingtoMahalanobisdistanceandjointprobability-Lineardose,quadraticfrequency,interaction(evaluablepopulation)
Supplementalfigures
FigureS1:Eosinophiliaforindividualparticipants(safetypopulation)
FigureS2:TPOantibodiesandTSHreceptorantibodies
FigureS3:Clinicalimagesandimmunohistochemicalstainingofpsoriasisinoneparticipantreceivingtreatmentwithaldesleukin0.32x106IU/m2everythreedays
FigureS4:PercentagechangeofCD19%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS5:PercentagechangeofCD19totalBcellsinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS6:PercentagechangeofCD3%inindividualparticipantsbydoseandfrequency(safetypopulation)
Page 2
2
FigureS7:PercentagechangeofCD3totalTcellsinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS8:PercentagechangeofCD4%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS9:PercentagechangeofCD4total%inindividualpatientsbydoseandfrequency(safetypopulation)
FigureS10:PercentagechangeofCD56%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS11:PercentagechangeofCD56totalNKcellsinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS12:PercentagechangeofCD8%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS13:PercentagechangeofCD8totalinindividualpatientsbydoseandfrequency(safetypopulation)
FigureS14:Percentagechangeoflymphocytescountinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS15:PercentagechangeofTreg%CD4Tcellsinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS16:PercentagechangeofTregabsoluteinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS17:PercentagechangeofTregCD25MeanFIinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS18:PercentagechangeofTregCD25MEFinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS19:PercentagechangeofNon-TregNaïve%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS20:PercentagechangeofNon-TregNaïveabsoluteinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS21:PercentagechangeofNon-TregTemra%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS22:PercentagechangeofNonTregTemraabsoluteinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS23:PercentagechangeofNonTregtotalmemory%inindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS24:PercentagechangeofNonTregtotalmemoryabsoluteinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS25:PercentagechangeofNonTregnaïve/memoryratioinindividualparticipantsbydoseandfrequency(safetypopulation)
Page 3
3
FigureS26:IL-2levelsinindividualparticipantsbydoseandfrequency(safetypopulation)
FigureS27:HbA1c(%)inindividualparticipantsbydoseandfrequency(analysispopulation)
StatisticalAnalysisPlan(SAP)
Page 4
4
Inclusioncriteria
• Type1diabetes
• 18-70yearsofage
• Durationofdiabeteslessthan60monthsfromdiagnosis
• Writteninformedconsenttoparticipate
Page 5
5
Exclusioncriteria
• Hypersensitivitytoaldesleukinoranyoftheexcipients
• Historyofseverecardiacdisease
• Historyofmalignancywithinthepast5years(withtheexceptionoflocalizedcarcinomaoftheskinthathadbeenresectedforcureorcervicalcarcinomainsitu
• Historyorconcurrentuseofimmunosuppressiveagentsorsteroids.
• Historyofunstablediabeteswithrecurrenthypoglycaemia
• ActiveautoimmuneHyperorhypothyroidism
• Historyoflivevaccinationtwoweekspriortofirsttreatment
• Activeclinicalinfection
• Majorpre-existingorgandysfunctionorpreviousorganallograft
• Femaleswhoarepregnant,lactatingorintendtogetpregnantduringthestudy
• Maleswhointendtofatherapregnancyduringthestudy
• Donationofmorethan500mlofbloodwithin2monthspriortoaldesleukinadministration
• Participationinaprevioustherapeuticclinicaltrialwithin2monthspriortoaldesleukinadministration
• AbnormalECG
• Abnormalfullbloodcount,chronicrenalfailure(Stage3,4,5)and/orevidenceofseverelyimpairedliverfunction(ALT/AST>3xULNatscreening;alkalinephosphataseandbilirubin2xULNatscreening(isolatedbilirubin>2xULNisacceptableifbilirubinisfractionatedanddirectbilirubin<35%)).
• PositiveHBsAgorHepCserologyorHIVtest
• Anymedicalhistoryorclinicallyrelevantabnormalitythatisdeemedbytheprincipalinvestigator/delegateand/ormedicalmonitortomakethepatientineligibleforinclusionbecauseofasafetyconcern.
Page 6
6
Studydrugadministration
Thetrialdrugwillbethestandardcommercialstockofaldesleukin(MarketingAuthorisationHolder:Novartis Pharmaceuticals UK Limited). Aldesleukin is produced by recombinant DNA technologyusinganEscherichiacolistrain,whichcontainsageneticallyengineeredmodificationofthehumaninterleukin2(IL-2)gene.
Thedrugisprovidedaspowderforsolutionforinjectionorinfusion.Forallinjections,aldesleukinisfirst reconstituted under aseptic conditions as per Proleukin® SmPC. Solutions are then furtherdiluted to the required concentration in glucose 5% and the appropriate volume drawn up intosterileU-100insulinsyringes.
The first dose of aldesleukin will be self-administered by participants at the trial site followinginstructionbyanappropriately traineddelegatedmemberof the trial team.Participants can thenadminister further doses either at the trial site or in the community. Alternatively, dosesmay beadministered by an appropriately qualifiedmember of the trial team. The date and time of eachdoseadministeredatthetrialsitewillberecordedinthesourcedocuments.Inthecommunity,thedateandtimeofeachdoseadministeredwillberecorded intheparticipant’sstudydiarythatwillbecome part of the source documents. The study diary, injection sites and count of unusedmedicationwillbecarriedoutateachstudyvisitwhileontreatmenttoconfirmcompliance.
Drugstorageandsupply
Commercialsupplyofaldesleukin,obtainedviausualhospitalroute,willbeusedforthisstudy.VialswillbestoredasperSmPC.at2ºCto8ºC(inarefrigerator)intheoriginalpackageinordertoprotectfrom light. The vials must not be frozen. Vials will be stored securely with access restricted toappropriateindividuals.
Previous (unlicensed)datasupportsstabilityandsterilityof reconstituteddiluted IL-2preparations(reconstitutedwithWaterforInjectionaspertheProleukin®SmPCandfurtherdilutedwithglucose5%) for up to 14 days at 2-8ºCwhen syringes are preparedby qualified health-care professionalsunderasepticconditions.Amaximumshelflifeof7dayswillbeassignedtotheprepareddosesforthisstudy.
The pharmacy at the participating site will dispense aldesleukin for this trial upon receipt of asuitablysignedtrialspecificprescription.Foreachindividualparticipant,multipleindividualdosesofa single concentration of the aldesleukin may be prepared under aseptic conditions foradministration in individual insulin syringes foreach7daysof the treatmentperiod.Alldosesnotusedwithinthe7-dayperiodwillbereturnedtothepharmacyatparticipatingsiteandarecordoftheirdisposalwillbemade.
Page 7
7
Co-primaryendpoints-DefinitionsofTregs,TeffsandCD25expressionwithintheCD3+CD4+fluorescence-activatedcellsorting(FACS)gate
Tregs:Tregs%CD25highCD127lowwithintheCD3+CD4+gate
CD25expressiononTregs:Meanfluorescenceintensity(MFI)ofCD25allophycocyanin(APC)withintheTreg(CD3+CD4+CD25highCD127low)gate
Teffs:Teffpopulations(non-Tregs)accountforalltheotherCD3+CD4+cellsthatarenotdefinedasTregswithintheCD3+CD4+gate:
• Effectormemory%CD45RA−CD62L−
• Centralmemory%CD45RA−CD62L+
• NaïveTeffs%CD45RA+CD62L+
• EffectormemoryRA+(TEMRA)CD45RA+CD62L−
• Centralmemory%+Effectormemory%=TotalMemoryeffectors%
• ChangeintheratioNaïveeffectors%:TotalMemoryeffectors%definestheTeffprimaryendpoint.
Page 11
11
Supplementarytables
TableS1DoseandfrequencyallocationaccordingtocohortLEAR
NING
COHORT1
0.09x106IU/m2
0.47x106IU/m2
0.20x106IU/m2
0.32x106IU/m2
14daily 2 2
10daily 2
5daily 2
2daily 2 2
COHORT2
10daily 1
5daily 2
4daily 1 1
3daily 1 2
CONFIRM
ING COHORT3
3daily 5 4
COHORT4
3daily 8
Page 12
12
TableS2Doseandfrequencyallocationaccordingtopopulation.
SAFETYPOPULATION
0.09x106IU/m2
0.47x106IU/m2
0.20x106IU/m2
0.32x106IU/m2
14daily 2 2 0 0
10daily 1 2 0 0
5daily 2 2 0 0
4daily 1 1 0 0
3daily 1 2 5 12
2daily 2 2 0 0
ANALYSISPOPULATION
14daily 1 2 0 0
10daily 1 2 0 0
5daily 2 2 0 0
4daily 1 0 0 0
3daily 1 2 4 8
2daily 1 1 0 0
Page 13
13
TableS3.Adverseeventsbyseverityandtypeinthesafetypopulation(N=37)
TypeofAdverseevent
Category Events Participants
TotalAEs MostcommonAEs(>10%)- Hypoglycaemia- Injectionsiteerythema- Injectionsitenodule
94(13.5%)230(33.1%)234(33.7%)
20(54.1%)35(94.6%)33(89.2%)
Adverseevents- Unexpected- Expectedadverseevents- Related- Unrelated
127(18.3%)567(81.7%)479(69.1)215(31.0%)
34(91.9%)37(100%)
Unexpected Unexpectedadverseeventsbyseverity(N/%)- Mild- Moderate
108(85%)19(15%)
32(86.5%)11(29.7%)
Mostcommon(>10%)unexpectedAEs- Headache- Nasopahryngitis
22(17.3%)18(14.2%)
12(32.4%)16(43.2%)
Unexpectedadverseevents(N/%)byrelatedness- Unrelated- Related
120(94.5%)7(5.5%)
Expected Expectedadverseeventsbyseverity(N/%)- Mild- Moderate
562(99.1%)5(0.9%)
37(100%)3(8.1%)
MostcommonexpectedAEs(>10%AEs)- Hypoglycaemia- Injectionsiteerythema- Injectionsitenodule
94(16.6%)230(40.6%)234(41.3%)
20(54.1%)35(94.6%)33(89.2%)
ExpectedAEs- Related- Unrelated
472(83.2%)95(16.8%)
UnrelatedAEs Unrelatedadverseeventsbyseverity(N/%)- Mild- Moderate
196(91.2%)19(8.8%)
35(94.59%)11(29.73%)
MostcommonunrelatedAEs(>10%)- Headache- Hypoglycaemia
22(10.2%)94(43.7%)
12(32.4%)20(54.1%)
Unrelatedadverseevents(N/%)- Expected- Unexpected
95(44.2%)120(55.8%)
21(56.7%)34(91.9%)
RelatedAEs Drug-relatedAEsaccordingtocohortsCohort1
- Injectionsiteerythema- Injectionsitenodule- Nauseaandvomitingsymptoms
Cohort2- Acne- Eosinophilia- Injectionsiteerythema- Injectionsitenodule
55(49.1%)56(50.0%)1(0.9%)2(2.0%)1(1.0%)50(49.0%)
11(91.7%)10(83.3%)1(8.3%)2(25.0%)1(12.5%)7(87.5%)
Page 14
14
- Malaise- Migraineheadaches
Cohort3- Injectionsiteerythema- Injectionsitenodule- Oropharyngealpain
Cohort4- Astheniccondition- Dryeye- Injectionsiteerythema- Injectionsitenodule- Nasopharyngitis
Nauseaandvomitingsymptoms
47(46.1%)1(1.0%)1(1.0%)68(55.3%)54(43.9%)1(0.8%)3(2.1%)1(0.7%)57(40.1%)77(54.2%)3(2.1%)1(0.7%)
6(75.0%)1(12.5%)1(12.5%)9(100%)9(100%)1(11.1%)3(37.5%)1(12.5%)8(100%)8(100%)3(37.5%)1(12.5%)
Drugrelatedinjectionsitereactionspernumberofdoses
- Injectionsiteerythemapernumberofdose
- Injectionsitenodulepernumberofdose
230/323(71.2%)234/323(72.4%)
DrugrelatedinjectionsitereactionspernumberofdosespercohortCohort1
- Injectionsiteerythemapernumberofdose
- InjectionsitenodulepernumberofdoseCohort2
- Injectionsiteerythemapernumberofdose
- InjectionsitenodulepernumberofdoseCohort3
- Injectionsiteerythemapernumberofdose
- InjectionsitenodulepernumberofdoseCohort4
- Injectionsiteerythemapernumberofdose
- Injectionsitenodulepernumberofdose
55/78(70.5%)56/78(71.8%)50/80(62.5%)47/80(58.8%)68/85(80.0%)54/85(63.5%)57/80(71.3%)77/80(96.3%)
11(91.7%)10(83.3%)7(87.5%)6(75.0%)9(100%)9(100%)8(100%)8(100%)
Page 15
15
TableS4.Safetyparameters(safetypopulation)
Parameter Baseline Followup Normalrange
hsCRP(mg/L)
2.55(±5.72) 1.90(±2.47) ≤3
Sodium(mmol/L)
138.75(±2.32) 138.6(±2.4) 133-146
Potassium(mmol/L)
4.36(±0.25) 4.35(±0.28) 3.5-5.3
Albumincorrectedcalcium(mmol/L)
2.32(±0.09) 2.36(0.13±) 2.08-2.65
Urea(mmol/L)
5.55(±1.6) 5.69(±1.34) 2.5-7.8
Creatinine(umol/L)
72.39(±14.92) 71.3(±11.3) F:44-97M:62-115
Alaninetransaminase(U/L)
21.97(±15.42) 24.9(±22.7) 7-40
Aspartateaminotransferase(U/L)
20.31(±7.23) 22.71(±12.76) ≤34
GGT(U/l)
17.11(±12.04) 20.9(±23.8) F:0-37M:0-72
Alkalinephosphatase(U/L)
74.11(±20.25) 80.8(±23.9) 30-130
TSH(mU/L)
1.55(±0.92) 1.85(±1.06) 0.35-5.50
FreeT4(pmol/L)
15.42(±2.4) 15.06(±1.74) 10.0-19.8
Redbloodcells(109/l) 4.79(±0.42) 4.74(±0.40) F:3.90-5.20M:4.00-5.65
Haemoglobin 144.9(±12.2) 142.0(±13.3) F:120-156M:135-172
Haematocrit(L/L) 0.42(±0.03) 0.41(±0.03) F:0.355-0.455M:0.395-0.505
Meancellhaemoglobin(pg) 30.21(±1.53) 29.93(±1.8) F:27.0-33.5M:27.0-33.5
Redcelldistributionwidth(%) 13.2(±0.54) 13.05(±0.71) 11.0-16.0
Plateletcount(109/l) 224.4(±44.4) 234.5(±51.6) 150-370
Whitebloodcells(109/l) 5.71(±1.76) 5.57(±1.65) 3.90-10.20
Neutrophils(109/l) 3.49(±1.61) 3.36(±1.36) 1.50-7.70
Lymphocytes(109/l) 1.53(±0.37) 1.56(±0.34) 1.50-7.70
Page 16
16
Monocytes(109/l) 0.41(±0.14) 0.42(±0.16) 0.10-0.90
Eosinophils(109/l) 0.16(±0.16) 0.15(±0.10) 0.10-0.90
Basophils(109/l) 0.05(±0.04) 0.04(±0.02) 0.00-0.20
Page 17
17
TableS5.ClinicalFACSanalysis(safetypopulation)
Parameter Baseline Followup
CD19% 12.2(±3.9) 12.3(±4.3)
CD19TotalBcells(*109/L) 0.2168(±0.17) 0.19(±0.08)
CD3% 74.8(±6.1) 75.1(±5.6)
CD3TotalTcells(*109/L) 1.16(±0.30) 1.19(±0.27)
CD4% 47.1(±7.5) 48.1(±8.1)
CD4Total(*109/L) 0.73(±0.23) 0.76(±0.21)
CD56% 12.4(±5.8) 12.1(±5.6)
CD56(*109/L) 0.19(±0.09) 0.18(±0.08)
CD8% 25.4(±6.6) 24.9(±6.7)
CD8Total(*109/L) 0.39(±0.13) 0.39(±0.14)
Lymphocytescount(*109/L) 1.53(±0.37) 1.58(±0.33)
Treg%CD4Tcells 7.13(±1.66) 7.28(±1.87)
TregAbsoulte(*109/L) 0.05(±0.02) 0.05(±0.02)
TregCD25MeanFI 2401.8(±794.7) 2292.4(±748.1)
TregCD25MEF 2863.8(±754.9) 2558.7(±520.5)
Non-Treggatedpanel Naïve% 42.4(±15.1) 39.6(±15.3)
Naïveabsolute(*109/L) 0.28(±0.14) 0.28(±0.15)
Temra% 1.01(±1.95) 0.7(±1.7)
Temraabsolute(*109/L) 0.006(±0.013) 0.004(±0.01)
Totalmemory% 56.6(±15.9) 59.9(±15.9)
Totalmemoryabsolute(*109/L) 0.38(±0.16) 0.41(±0.14)
Naïve/memoryratio 0.94(±0.84) 0.84(±0.79)
Page 18
18
TableS6.AICforallmodels(analysispopulation)
Model TregAIC CD25AIC TeffAIC
Lineardose,linearferquency 245.8 235.93 243.89
Quadraticdose,linearfrequency
243.55 236.14 245.85
Lineardose,quadraticfrequency
245.72 219.52 240.79
Quadraticdose,quadraticfrequency
245.27 215.0 238.63
Logdose,linearfrequency 244.26 235.04 243.95
Lineardose,logfrequency 244.27 228.82 244.73
Logdose,logfrequency 242.88 228.29 244.71
Lineardose,quadraticfrequency,interaction
246.66 213.44 236.82
Page 19
19
TableS7.Estimatedtargetdose/frequency
Model Bestdose
DoseSE
DoseCI
BestFrequency
FrequencySE
FrequencyCI
Lineardose,linearfrequency
-0.082 1.927 -3.858,3.694
-2.9 31.9 65.4,59.6
Quadraticdose,linearfrequency
0.133 0.154 -0.17,0.435
-0.7 10.1 -20.4,19.0
Lineardose,quadraticfrequency
0.240 0.114 0.017,0.463
3.0 0.5 1.7,3.5
Quadraticdose,quadraticfrequency
0.186 0.048 0.093,0.279
2.6 0.5 1.7,3.5
Logdose,linearfrequency
0.067 0.420 -0,757,0.891
-2.5 27.4 -56.3,51.2
Lineardose,logfrequency
0.170 0.482 -0.775,1.115
2.4 2.7 -2.8,7.7
Logdose,logfrequency
0.168 0.252 -0.327,0.662
2.5 2.2 -1.8,6.9
Lineardose,quadraticfrequency,interaction
0.239 0.126 -0,008,0.485
2.9 0.8 1.4,4.4
Page 20
20
TableS8.Bestestimatedallowabledoes/frequencyaccordingtoMahalanobisdistanceandjointprobability–Lineardose,quadraticfrequency,interaction(analysispopulation)
Dose Frequency MahalanobisDistance
JointProbability
0.26
3 0.044 0.742
0.25 3 0.062 0.7370.27 3 0.111 0.7160.24 3 0.134 0.7020.28 3 0.186 0.661
Page 21
21
TableS9.Bestestimatedallowabledose/frequencyaccordingtoMahalanobisdistanceandjointprobability-Lineardose,quadraticfrequency,interaction(evaluablepopulation)
Dose Frequency MahalanobisDistance
Joint
Probability
0.21 3 0.124 0.696
0.22 3 0.12 0.694
0.2 3 0.16 0.663
0.23 3 0.151 0.658
0.19 3 0.213 0.603
Page 22
22
SupplementaryFigures
FigureS1.Eosinophiliaforindividualparticipants(safetypopulation)
Oneparticipantonaldesleukin0.47x106IU/m2every4daysdevelopedtransienteosinophilia(red);pre-existingeosinophiliaresolvedintwoparticipantsreceiving0.32x106IU/m2every3days(purple),and0.09x106IU/m2every2days(blue),respectively.
1 2 3 4 5 6 7 8 9 10 11 120.0
0.5
1.0
1.5
Visit number
Eosi
noph
ils (1
09 /L)
Page 23
23
FigureS2.TPOantibodiesandTSHreceptorantibodies.Datashownforindividualpatientsinsafetypopulation.
NoparticipantdevelopeddenovoTPOantibodies(A)orTSHreceptorantibodies(B)duringthetrial.Tickedlineindicatesupperlimitofnormalrange.
1 1210
100
1000
Visit number
Log1
0 TP
O a
ntib
odie
s (IU
/ml)
1 120.0
0.5
1.0
1.5
Visit number
TSH
rece
ptor
ant
ibod
ies
(IU/L
)
A B
Page 24
24
FigureS3.Clinicalimagesandimmunohistochemicalstainingofpsoriasisinoneparticipantreceivingtreatmentwithaldesleukin0.32x106IU/m2everythreedays.
(A-F)Clinicalimages:Therewasnochangeinplaquesize,andplaquenumber(threelesionsonrightelbow, abdomen, and left ear; data not shown) during treatment. Image A to E show plaque onelbowat subsequentdosing visits 3 (A), 4 (B), 8 (C), 9 (D), and10 (E).At followup, anadditionalplaquewasobservedontheabdomen,whilethesizeofpre-existingplaquesremainedstable(F).
(G-L)Immunohistochemicalstaining:skinpunchbiopsiesofthepsoriaticplaqueonrightelbowweretakenatvisit10andatfollowupvisit12.HistopathologysectionswerestainedforCD3before(G)andafter (J) treatment,CD4before(H)andafter (K)treatment,andFOXP3before(I)andafter (L)treatment.Imagesareshown10xenlarged.CD3,CD4andFOXP3positivecellswerecountedinfiverandomfieldsofviewat100xmagnification.FOXP3toCD3ratio(0.17before,0.17after)andFOXP3toCD4ratio(0.13before,0.15after)remainedunchanged.
Page 25
25
FigureS4:PercentagechangeofCD19%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 26
26
FigureS5:PercentagechangeofCD19totalBcellsinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 27
27
FigureS6:PercentagechangeofCD3%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 28
28
FigureS7:PercentagechangeofCD3totalTcellsinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 29
29
FigureS8:PercentagechangeofCD4%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 30
30
FigureS9:PercentagechangeofCD4totalinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 31
31
FigureS10:PercentagechangeofCD56%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 32
32
FigureS11:PercentagechangeofCD56totalNKcellsinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 33
33
FigureS12:PercentagechangeofCD8%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 34
34
FigureS13:PercentagechangeofCD8totalinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 35
35
FigureS14:Percentagechangeoflymphocytescountinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 36
36
FigureS15:PercentagechangeofTreg%CD4Tcellsinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 37
37
FigureS16:PercentagechangeofTregabsoluteinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 38
38
FigureS17:PercentagechangeofTregCD25MeanFIinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 39
39
FigureS18:PercentagechangeofTregCD25MEFinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 40
40
FigureS19:PercentagechangeofNon-TregNaïve%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 41
41
FigureS20:PercentagechangeofNon-TregNaïveabsoluteinindividualparticipants(eachline)bydoseandfrequency(safetypopulation
Page 42
42
FigureS21:PercentagechangeofNon-TregTemra%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 43
43
FigureS22:PercentagechangeofNon-TregTemraabsoluteinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 44
44
FigureS23:PercentagechangeofNon-Tregtotalmemory%inindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 45
45
FigureS24:PercentagechangeofNon-Tregtotalmemoryabsoluteinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 46
46
FigureS25:PercentagechangeofNon-Tregnaïve/memoryratioinindividualparticipants(eachline)bydoseandfrequency(safetypopulation)
Page 47
47
FigureS26:IL-2levelsinindividualparticipantsbydoseandfrequency(safetypopulation)
0.001
0.01
0.1
1
10
0 5 10 15
0.09 x106 IU/m2, 2−day
0.001
0.01
0.1
1
10
0 10 20 30
0.09 x106 IU/m2, 3−day
0.001
0.01
0.1
1
10
0 10 20 30 40
0.09 x106 IU/m2, 4−day
0.001
0.01
0.1
1
10
0 10 20 30 40
0.09 x106 IU/m2, 5−day
0.001
0.01
0.1
1
10
0 20 40 60 80 100
0.09 x106 IU/m2, 10−day
0.001
0.01
0.1
1
10
0 20 40 60
0.09 x106 IU/m2, 14−day
0.001
0.01
0.1
1
10
0 10 20 30
0.20 x106 IU/m2, 3−day
0.001
0.01
0.1
1
10
0 10 20 30
0.32 x106 IU/m2, 3−day
0.001
0.01
0.1
1
10
0 5 10 15
0.47 x106 IU/m2, 2−day
0.001
0.01
0.1
1
10
0 10 20 30
0.47 x106 IU/m2, 3−day
0.001
0.01
0.1
1
10
0 10 20 30 40
0.47 x106 IU/m2, 4−day
0.001
0.01
0.1
1
10
0 10 20 30 40 50
0.47 x106 IU/m2, 5−day
0.001
0.01
0.1
1
10
0 10 20 30 40
0.47 x106 IU/m2, 10−day
0.001
0.01
0.1
1
10
0 20 40 60
0.47 x106 IU/m2, 14−day
IL−2
(IU
/ml)
Days
Page 48
48
FigureS27:HbA1c(%)inindividualparticipants(eachline)bydoseandfrequency(analysispopulation)
5
7
9
11
13
−10 0 10 20 30 40 50
0.09 x106 IU/m2, 2−day
5
7
9
11
13
−10 0 10 20 30 40 50 60
0.09 x106 IU/m2, 3−day
5
7
9
11
13
−20 −10 0 10 20 30 40 50 60 70
0.09 x106 IU/m2, 4−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70
0.09 x106 IU/m2, 5−day
5
7
9
11
13
−20 0 20 40 60 80 100 120
0.09 x106 IU/m2, 10−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70 80 90
0.09 x106 IU/m2, 14−day
5
7
9
11
13
−20 −10 0 10 20 30 40 50 60
0.20 x106 IU/m2, 3−day
5
7
9
11
13
−30 −20 −10 0 10 20 30 40 50 60
0.32 x106 IU/m2, 3−day
5
7
9
11
13
−10 0 10 20 30 40 50
0.47 x106 IU/m2, 2−day
5
7
9
11
13
−10 0 10 20 30 40 50 60
0.47 x106 IU/m2, 3−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70
0.47 x106 IU/m2, 4−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70 80
0.47 x106 IU/m2, 5−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70
0.47 x106 IU/m2, 10−day
5
7
9
11
13
−10 0 10 20 30 40 50 60 70 80 90
0.47 x106 IU/m2, 14−day
HbA
1c (%
)
Days